Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Large Decline in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 100 shares, a drop of 85.7% from the October 15th total of 700 shares. Based on an average daily volume of 3,500 shares, the days-to-cover ratio is presently 0.0 days.

Santen Pharmaceutical Stock Performance

OTCMKTS:SNPHY traded up $0.16 during mid-day trading on Wednesday, hitting $10.78. 1,357 shares of the company’s stock traded hands, compared to its average volume of 6,332. Santen Pharmaceutical has a 1 year low of $8.72 and a 1 year high of $13.00. The firm’s 50 day simple moving average is $12.06 and its 200 day simple moving average is $11.29.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.